Biogen lifts full-year profit forecast as Tecfidera boosts quarter

(Reuters) – Biogen Inc (BIIB.O) raised its 2020 earnings forecast after better-than-expected sales of its multiple sclerosis treatment Tecfidera helped the drugmaker beat second-quarter profit estimates. The company’s shares rose 2.8% before the opening bell as the results allayed investor